Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 26, 2012

View Archived Issues

Team at Merrimack Pharmaceuticals designs new bispecific antibodies

AstraZeneca profiles novel dual chemokine CCR3/histamine H1 receptor antagonists

Gilead's GS-967 suppresses experimental arrhythmias

New TRPV4 channel ligands divulged by Shionogi

Promising results presented for a novel malaria vaccine

Novel antipsychotics created at Roche

King Saud University and Terramark design new anti-inflammatory agents

Arena Pharmaceuticals divulges novel GRP119 receptor agonists

Ligand Pharmaceuticals presents a novel HepDirect prodrug with excellent oral bioavailability

Enhanced genetically encoded calcium indicators described / News in Context: Optogenetics

ImmunoGen patents novel cancer therapeutics

New antivirals designed by University of Pennsylvania

University of Missouri discloses novel TNF-alpha production inhibitors

EMA recommends granting orphan status to Aspireo's somatoprim

GS-432780-5 and GS-443023-6 show promise in mouse models of chronic liver injury

Alfama designs novel therapy against liver pathology

Discovery of AZ-12436092 reported by AstraZeneca researchers

Pharming receives milestone payment from Santarus

CLSPN gene mutations identified in glioma patients

Phase IIb JX-594 trial begins in Hong Kong

Murdoch Childrens opens Australian site in global study of BioMarin's achondroplasia treatment

AstraZeneca and Pfizer partnership establishes life sciences research center

Recruitment complete in phase I study of ATX-MS-1467

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...